Description

CGT Global Cryopreserved Leukopaks are collected from IRB consented healthy donors at our FDA-registered Stem Cell Collection Center. Cell-rich peripheral blood mononuclear cells (PBMCs) are extracted using a continuous flow centrifugation system. Leukopaks are collected directly into a sterile collection bag containing the anticoagulant ACD-A. Besides the PBMCs, which consist of lymphocytes and monocytes, each Leukopak will also contain minimal amounts of granulocytes and red blood cells.

The following are mean percentages of cell populations for a single donor Leukopak prior to cryopreservation:

• T cells – 55%
• Monocytes – 27%
• B cells – 9%
• NK cells – 8%
• CD34+ stem cells – 0.1%
• Granulocytes – 2.4%

We do not guarantee the percentage of cell populations in a Leukopak, as they can vary from donor to donor.

Leukopaks are quickly Cryopreserved  after collection in a medium containing the cryoprotective agent CryoStorTM (10% DMSO) using a controlled rate freezer to ensure maximum viability.

Before cryopreservation, the Total nucleated cell (TNC) counts and viability testing are performed. For optimal cell recovery and viability, we recommend following our Thawing Protocol found under the Technical Resources tab. Deviations from this protocol can compromise viability and cell recovery.

For global shipments, we highly recommend shipping Cryopreserved Leukopaks in an LN2 cryoshipper to maintain proper temperatures for the duration of the transit time. Upon arrival, Cryopreserved Leukopaks should be stored in the vapor phase of liquid nitrogen or thawed immediately for use.

Custom Orders

Design the right Leukopak for your research needs. View our custom orders to see what options we have available.